Targeting diacylglycerol kinase α impairs lung tumorigenesis by inhibiting cyclin D3

Background: Diacylglycerol kinase α (DGKA) is the first member discovered from the diacylglycerol kinase family, and it has been linked to the progression of various types of tumors. However, it is unclear whether DGKA is linked to the development of lung Cancer.

Methods: We investigated the levels of DGKA in the lung Cancer tissues. Cell growth assay, colony formation assay and EdU assay were used to examine the effects of DGKA-targeted siRNAs/shRNAs/drugs on the proliferation of lung Cancer cells in vitro. Xenograft mouse model was used to investigate the role of DGKA inhibitor ritanserin on the proliferation of lung Cancer cells in vivo. The downstream target of DGKA in lung tumorigenesis was identified by RNA sequencing.

Results: DGKA is upregulated in the lung Cancer cells. Functional assays and xenograft mouse model indicated that the proliferation ability of lung Cancer cells was impaired after inhibiting DGKA. And cyclin D3(CCND3) is the downstream target of DGKA promoting lung Cancer.

Conclusions: Our study demonstrated that DGKA promotes lung tumorigenesis by regulating the CCND3 expression and hence it can be considered as a potential molecular biomarker to evaluate the prognosis of lung Cancer patients. What's more, we also demonstrated the efficacy of ritanserin as a promising new medication for treating lung Cancer.

CCND3; DGKA; lung cancer; tumorigenesis.